{
  "trial_id": "NCT02512068",
  "trial_group": "chronic kidney disease",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, body mass index (BMI), duration of type 2 diabetes mellitus, baseline HbA1c, fasting C-peptide value, hemoglobin value, creatinine clearance (Ccr), glycoalbumin value, presence of severe renal impairment or end-stage renal disease, use of antidiabetic medications, history of hemodialysis, baseline blood pressure, baseline liver function tests (AST, ALT, total bilirubin), history of cardiac diseases, history of cerebrovascular disorders, history of pancreatic or hematological diseases, history of hypoglycemia, history of hypertension, alcohol consumption, history of drug abuse, pregnancy status, use of contraception.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "BMI",
          "body mass index (BMI)"
        ],
        [
          "Duration of Diabetes",
          "duration of type 2 diabetes mellitus"
        ],
        [
          "Hemoglobin A1c (HbA1c)",
          "baseline HbA1c"
        ],
        [
          "Fasting C-Peptide",
          "fasting C-peptide value"
        ],
        [
          "Creatinine Clearance",
          "creatinine clearance (Ccr)"
        ],
        [
          "Glycoalbumin",
          "glycoalbumin value"
        ],
        [
          "Undergoing Hemodialysis",
          "history of hemodialysis"
        ],
        [
          "Antidiabetic Drug at the start of the screening period (Week -6)",
          "use of antidiabetic medications"
        ],
        [
          "Pregnancy Status",
          "pregnancy status"
        ],
        [
          "Use of Contraception",
          "use of contraception"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race and Ethnicity Not Collected",
        "Region of Enrollment",
        "Exercise Program",
        "Antidiabetic Drug at the start of the screening period (Week -6): Rapid-acting Insulin Secretagogue",
        "Antidiabetic Drug at the start of the screening period (Week -6): Mitiglinide Calcium Hydrate",
        "Antidiabetic Drug at the start of the screening period (Week -6): Repaglinide",
        "Antidiabetic Drug at the start of the screening period (Week -6): \u03b1-Glucosidase Inhibitor",
        "Antidiabetic Drug at the start of the screening period (Week -6): Acarbose",
        "Antidiabetic Drug at the start of the screening period (Week -6): Miglitol",
        "Antidiabetic Drug at the start of the screening period (Week -6): Voglibose",
        "Antidiabetic Drug at the start of the screening period (Week -6): Insulin Preparation",
        "Antidiabetic Drug at the start of the screening period (Week -6): Type of Insulin Preparation",
        "Estimated Glomerular Filtration Rate (eGFR)",
        "Fasting Plasma Glucose",
        "Fasting Glucagon",
        "Dipeptidyl-Peptidase-4 (DPP-4) Activity"
      ],
      "remaining_candidate_features": [
        "hemoglobin value",
        "presence of severe renal impairment or end-stage renal disease",
        "baseline blood pressure",
        "baseline liver function tests (AST, ALT, total bilirubin)",
        "history of cardiac diseases",
        "history of cerebrovascular disorders",
        "history of pancreatic or hematological diseases",
        "history of hypoglycemia",
        "history of hypertension",
        "alcohol consumption",
        "history of drug abuse"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Baseline HbA1c, Fasting C-peptide, Hemoglobin, Creatinine clearance, Glycoalbumin, Duration of diabetes, Use of antidiabetic medications, Hemodialysis status,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Duration of Diabetes",
          "Duration of diabetes"
        ],
        [
          "Undergoing Hemodialysis",
          "Hemodialysis status"
        ],
        [
          "Antidiabetic Drug at the start of the screening period (Week -6)",
          "Use of antidiabetic medications"
        ],
        [
          "Creatinine Clearance",
          "Creatinine clearance"
        ],
        [
          "Hemoglobin A1c (HbA1c)",
          "Baseline HbA1c"
        ],
        [
          "Fasting C-Peptide",
          "Fasting C-peptide"
        ],
        [
          "Glycoalbumin",
          "Glycoalbumin"
        ]
      ],
      "remaining_reference_features": [
        "Race and Ethnicity Not Collected",
        "BMI",
        "Exercise Program",
        "Antidiabetic Drug at the start of the screening period (Week -6): Rapid-acting Insulin Secretagogue",
        "Antidiabetic Drug at the start of the screening period (Week -6): Mitiglinide Calcium Hydrate",
        "Antidiabetic Drug at the start of the screening period (Week -6): Repaglinide",
        "Antidiabetic Drug at the start of the screening period (Week -6): \u03b1-Glucosidase Inhibitor",
        "Antidiabetic Drug at the start of the screening period (Week -6): Acarbose",
        "Antidiabetic Drug at the start of the screening period (Week -6): Miglitol",
        "Antidiabetic Drug at the start of the screening period (Week -6): Voglibose",
        "Antidiabetic Drug at the start of the screening period (Week -6): Insulin Preparation",
        "Antidiabetic Drug at the start of the screening period (Week -6): Type of Insulin Preparation",
        "Estimated Glomerular Filtration Rate (eGFR)",
        "Fasting Plasma Glucose",
        "Fasting Glucagon",
        "Dipeptidyl-Peptidase-4 (DPP-4) Activity"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Hemoglobin"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, Hemoglobin A1c, Fasting C-peptide, Hemoglobin, Creatinine Clearance, Insulin Dose, Antidiabetic Medication Use, Duration of Diabetes.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "BMI",
          "Body Mass Index"
        ],
        [
          "Duration of Diabetes",
          "Duration of Diabetes."
        ],
        [
          "Creatinine Clearance",
          "Creatinine Clearance"
        ],
        [
          "Hemoglobin A1c (HbA1c)",
          "Hemoglobin A1c"
        ],
        [
          "Fasting C-Peptide",
          "Fasting C-peptide"
        ]
      ],
      "remaining_reference_features": [
        "Race and Ethnicity Not Collected",
        "Exercise Program",
        "Undergoing Hemodialysis",
        "Antidiabetic Drug at the start of the screening period (Week -6)",
        "Antidiabetic Drug at the start of the screening period (Week -6): Rapid-acting Insulin Secretagogue",
        "Antidiabetic Drug at the start of the screening period (Week -6): Mitiglinide Calcium Hydrate",
        "Antidiabetic Drug at the start of the screening period (Week -6): Repaglinide",
        "Antidiabetic Drug at the start of the screening period (Week -6): \u03b1-Glucosidase Inhibitor",
        "Antidiabetic Drug at the start of the screening period (Week -6): Acarbose",
        "Antidiabetic Drug at the start of the screening period (Week -6): Miglitol",
        "Antidiabetic Drug at the start of the screening period (Week -6): Voglibose",
        "Antidiabetic Drug at the start of the screening period (Week -6): Insulin Preparation",
        "Antidiabetic Drug at the start of the screening period (Week -6): Type of Insulin Preparation",
        "Estimated Glomerular Filtration Rate (eGFR)",
        "Fasting Plasma Glucose",
        "Glycoalbumin",
        "Fasting Glucagon",
        "Dipeptidyl-Peptidase-4 (DPP-4) Activity"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Hemoglobin",
        "Insulin Dose",
        "Antidiabetic Medication Use"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 2 diabetes mellitus, fasting C-peptide value, hemoglobin value, HbA1c value, glycoalbumin value, creatinine clearance (Ccr), history of antidiabetic medication use, history of insulin use, presence of severe renal impairment or end-stage renal disease, presence of hemodialysis or peritoneal dialysis.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "BMI",
          "body mass index (BMI)"
        ],
        [
          "Duration of Diabetes",
          "duration of type 2 diabetes mellitus"
        ],
        [
          "Fasting C-Peptide",
          "fasting C-peptide value"
        ],
        [
          "Hemoglobin A1c (HbA1c)",
          "HbA1c value"
        ],
        [
          "Glycoalbumin",
          "glycoalbumin value"
        ],
        [
          "Creatinine Clearance",
          "creatinine clearance (Ccr)"
        ],
        [
          "Antidiabetic Drug at the start of the screening period (Week -6)",
          "history of antidiabetic medication use"
        ],
        [
          "Undergoing Hemodialysis",
          "presence of hemodialysis or peritoneal dialysis"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race and Ethnicity Not Collected",
        "Region of Enrollment",
        "Exercise Program",
        "Antidiabetic Drug at the start of the screening period (Week -6): Rapid-acting Insulin Secretagogue",
        "Antidiabetic Drug at the start of the screening period (Week -6): Mitiglinide Calcium Hydrate",
        "Antidiabetic Drug at the start of the screening period (Week -6): Repaglinide",
        "Antidiabetic Drug at the start of the screening period (Week -6): \u03b1-Glucosidase Inhibitor",
        "Antidiabetic Drug at the start of the screening period (Week -6): Acarbose",
        "Antidiabetic Drug at the start of the screening period (Week -6): Miglitol",
        "Antidiabetic Drug at the start of the screening period (Week -6): Voglibose",
        "Antidiabetic Drug at the start of the screening period (Week -6): Insulin Preparation",
        "Antidiabetic Drug at the start of the screening period (Week -6): Type of Insulin Preparation",
        "Estimated Glomerular Filtration Rate (eGFR)",
        "Fasting Plasma Glucose",
        "Fasting Glucagon",
        "Dipeptidyl-Peptidase-4 (DPP-4) Activity"
      ],
      "remaining_candidate_features": [
        "race",
        "ethnicity",
        "hemoglobin value",
        "history of insulin use",
        "presence of severe renal impairment or end-stage renal disease"
      ]
    }
  }
}